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There are two reasons for studying the possible role of the Epstein-Barr virus (EBV) 
in  relation  to  rheumatoid  arthritis  (RA).  The  first  is  the  recent  demonstration  by 
Alspaugh and co-workers that EBV infection of normal peripheral blood lymphocytes 
induces  the  development  in  these  cells  of a  nuclear  antigen  against  which  most 
patients with RA have precipitating antibodies  (I). The second reason is that EBV is 
a  naturally  occurring,  polyclonal  activator  of antibody  production  by  human  B 
lymphocytes (2, 3). 
In the present experiments,  we have asked to what extent RA and normal subjects 
have B lymphoeytes which can be induced by EBV to secrete anti-IgG antibodies. At 
the  same  time,  we  have  determined  the  degree  to  which  lymphoeytes  from  RA 
patients spontaneously transform in the absence of EBV infection.  EBV nucleic acid 
can be detected in most permanent lines of human B cells (4). In most cases, therefore, 
EBV  plays  an  essential  role  in  the  in  vitro  transformation  of human  B  cells  to 
permanent lines. If RA lymphocytes undergo morphologic transformation and become 
permanent  lines  more  readily  than  do  normal  lymphocytes,  one  might  wonder 
whether or not they either contain more EBV genomes per cell than normal lympho- 
cytes, or are abnormally responsive to EBV infection. 
Materials  and Methods 
Source.  50 ml of heparinized  blood was obtained  from  I 1 patients with seropositive RA. 
These patients met the American Rheumatism Association criteria (8) for diagnosis and were 
all currently under treatment at the Scripps Clinic and Research Foundation.  10 other samples 
of the  same  volume  were  obtained  from  healthy  persons  having  no  prior  diagnosis  of a 
rheumatic disorder and using no medications. 
Virus.  EBV  was  obtained  from  the  B95-8  marmoset  lymphoblastoid  line,  processed  as 
described by Miller and Lipman and Thorley-Lawson et al., and frozen until use (6, 7). 
Cell Separation and Culture Procedure.  Mononuclear cells were isolated from 50 ml heparinized 
blood by Ficoll-Hypaque sedimentation (8) followed by five washes in serum-free medium, and 
resuspension in RPMI-1640 and 10% fetal calf serum (Flow Laboratories, Inc., Roekville, Md.) 
at  a  concentration of 10  7 eells/ml.  1 ml of EBV was used to infect  1  ×  107 cells.  An equal 
volume of RPMI-1640 with  10% fetal bovine serum was added to duplicate control cells. Cells 
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were gently agitated at  37°C  for  1 h  and then resuspended to a concentration of 1  ×  106 
cells/ml. Cells were again agitated gently at 37°C for 20 rain, then centrifuged at 500 g for 10 
rain at 37°C.  The supematant fluid was removed to be assayed later as a zero time control for 
total IgG and I~M anti-IgG production. Control and infected cells were cultured at concentra- 
tions of 1 X  10°/ml in duplicate Coming T25 flash (Coming Glass Works, Science Products 
Div., Coming, N. Y.) at final vol of 10 ml in RPMI-1640 containing 10% fetal bovine serum. 
The supernatant  fluid was removed from each culture by centrifugation at weekly intervals 
and frozen at -20°C until subsequently assayed for total IgM and IgM anti-IgG production. 
Cell pellets were resuspended in an equal volume of fresh medium and replaced in the original 
flasks. 
Transformation Assay.  The  outgrowth  of transformed  lymphocytes was  assayed  visually 
according to the system of Thorley-Lawson et al.  (7). In this system a score of one represents 
dead cells; two, living but not transformed cells; three, enlarged cells and cells in clumps; and 
four, proliferating cells overrunning the culture. 
Radioimmunoassay.  IgM  anti-IgG in  the  culture  supemates was analyzed by solid  phase 
radioimmunoassay exactly as previously described,  using pooled human IgG (Sigma Chemical 
Co., St. Louis, Mo.) as antigen (9). The cpm anti-IgG bound were converted to nanograms of 
IgM anti-IgG per milliliter using a standard curve containing known quantities of a purified 
monoclonal IgM (k) anti-IgG (IgM-Si)  isolated  from the serum of a patient with cryoglobuli- 
hernia (10). 
Total IgM in the culture supernates was also analyzed by solid phase radioimmunoassay, 
performed exactly the same as the IgM anti-IgG assay except that the tubes were coated with 
5 #g/ml of purified unlabeled anti-IgM rather than 60 #g/ml human IgG. Again, counts were 
transformed to nanograms IgM per milliliter using a  standard  curve containing  the  same 
monoclonal IgM (k) protein as used for the IgM anti-IgG assay. 
Depletion Experiments.  Human  Cohn  Fraction  II  (Sigma Chemical  Co.)  was  coupled  to 
cyanogen bromide activated Sepharose 4B (Pharmacia Fine Chemicals, Inc. Piscataway, N. J.) 
according to the manufacturer's directions.  To  1 ml of a  50% slurry of IgG-Sepharose was 
added 2 ml of undiluted supematant fluid. After shaking overnight at room temperature the 
IgG-Sepharose was removed by centrifugation and the supernate was assayed for total IgM 
and IgM anti-IgG. 
Results 
IgM Anti-IgG Secretion.  Fig.  1 shows the amount of IgM anti-IgG as measured by 
radioimmunoassay released into the supernatant fluids at 6-day intervals by cells from 
patients with RA and normal controls, either infected with EBV, or uninfected. The 
points of significance are:  (a) not only the lymphocytes of patients with RA, but also 
those of some normal individuals made anti-IgG when infected with EBV, although 
the rheumatoid lymphocytes made significantly more than did the normal lympho- 
cytes; (b) the peak of anti-IgG secretion was seen at 18 and 24 days after the initiation 
of culture  in  both  rheumatoids  and  normals;  (c)  while  the  lymphocytes of normal 
donors produced little or no anti-IgG in the absence of EBV infection, the lymphocytes 
from RA patients produced small but significant quantities  in an early (6-12 days) 
peak. 
Total IgM Secretion.  As shown in Fig. 2, EBV-infected lymphocytes produced more 
IgM than uninfected cells over the 30-day period of the experiments. Of note, whether 
infected with  EBV  or uninfected,  both the  normal and  RA lymphocytes produced 
similar  amounts  of  IgM  with  the  same  time  course.  Thus,  it  follows  that  the 
lymphocytes from patients with RA made more IgM anti-IgG relative to the amount 
of IgM being produced in the culture than did cells from normal subjects. As shown 
in Fig. 3, when measured by radioimmunoassay, 30  +  8% of the IgM in the plasmas 
of the RA patients had anti-IgG activity, and this percentage was generally the same SLAUGHTER  ET  AL.  BRIEF  DEFINITIVE  REPORT  1431 
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IgM  anti-IgG  production  by  peripheral  blood  mononuclear  cells  from  patients  with 
arthritis (R) and normal subjects (N). Cells from 10 patients with RA (R, 0) and 9 normal subjects 
(N, C)), either infected with  EBV  (upper panel)  or uninfected (lower panel)  were cultured at  a 
concentration  of  10  s  cells/ml  in  RPMI-1640  medium  with  10%  fetal  bovine  serum.  At  6-day 
intervals the cells were centrifuged and the culture media removed for assay of lgM anti-IgG by 
radioimmunoassay. Each point represents the mean  +  SEM  amount  of anti-IgG  produced per 
milliliter by the respective patient groups over the previous 6 day interval. 
Fla.  2.  Total  IgM  production by peripheral blood mononuclear cells from patients with rheu- 
matoid  arthritis  (R)  and  normal  subjects  (N).  This  experiment was  performed using the same 
culture fluids as described in Fig.  1, except that total IgM was determined by radioimmunoassay. 
4] EDY infected  "~ ~..IN 
x  BE  4- Uninfected 
~2  ~. 
-'-/  lo  1 
O'  Plasma  18  24  30 
O|~f  Day  Bay  guy  O  8  12  18  24  3U 
Culture Supsrnates  Days in Culture 
Fio.  3.  Percentage of IgM with anti-IgG activity in plasma and in culture supernates from EBV 
infected mononuclear cells from patients with rheumatoid arthritis  (R)  and normal subjects (N). 
This figure was derived using the data from Figs. 1 and 2, and by assaying the mean  :t:  SEM IgM 
and IgM anti-lgG in the plasma from the same patients whose cells had been placed in culture. 
Fro.  4.  Transformation state of rheumatoid and normal peripheral blood mononuclear cells in 
tissue culture. The transformation state of either EBV infected (upper panel) or uninfected (lower 
panel) peripheral blood mononuclear cells from patients with rheumatoid arthritis (R, O) or normal 
subjects (N, O) was assayed visually by the method of Thorley-Lawson et al. (7). Grade 2  ~  living 
but untransformed cells. Grade 3  =  transformed cells in clumps. Grade 4  =  dividing cells over- 
running the culture. 
in the various supernates of the cultured cells. On the other hand, 2  +_.  1% of the IgM 
in the normal plasmas was detected as anti-IgG. This percentage was nearly the same 
in the supernatants of the 12-day cultures but gradually rose to 7.5  +  2% by 30 days. 
Specificity of the IgM Anti-IgG.  Greater than 90% of the anti-IgG antibody detected 
in  24-day  supernates  of EBV-stimulated  RA  mononuclear  cells  was  removed  by 
absorption with IgG-Sepharose. On the other hand, only 50-70% of the IgM anti-IgG 
from two randomly selected supernates from EBV-stimulated normal mononuclear 1432  SLAUGHTER  ET  AL.  BRIEF  DEFINITIVE REPORT 
cells  harvested  at  the  same  time  was  specifically removed by  immunoabsorption, 
suggesting  that  this  antibody  was  of lower  affinity than  the  anti-IgG  in  the  RA 
supernatants.  Approximately  1-2% of the IgM  in all samples was  detected as IgM 
anti-IgG which could not be absorbed. 
Cellular Transformation.  Fig. 4 shows the transformation indices for rheumatoid and 
normal lymphocytes for the first 30 days after initiation of culture. One culture from 
an  RA patient  and one from a  control died early in  the course of the experiment, 
leaving 9  derived from normals and  10 from RA patients.  It is from these that the 
data  in  the  figure were  compiled.  In  the  EBV  infected groups,  both  normal  and 
rheumatoid lymphocytes showed rapid development of transformation with similar 
time courses.  On  the other hand,  noninfected cell cultures from patients  with  RA 
transformed more rapidly, and to a higher degree, than did normal lymphocytes. This 
was most marked at 12-18 days. The differences be,tween the noninfected rheumatoid 
and normal cultures at any single time point were not significant. However, when all 
points from days  18-30 were subjected to variance analysis, a  significant difference 
between the two groups was found (F  ~-  11.6, P <  0.01). Furthermore, only 2 of 10 
cultures of normal lymphocytes, but 6 of 11 cultures of RA lymphocytes, developed 
into continuous B lymphoid cell lines. The time interval for the establishment of the 
permanent lines ranged from 3 to 10 wk. 
Discussion 
The  studies  reported  herein  show  that  in  vitro  infection  of peripheral  blood 
lymphocytes with EBV can induce the synthesis of IgM anti-IgG antibody, not only 
in  patients  with  RA  but  also  in  normal  subjects.  The  autoantibody  production 
probably  results  from  polyclonal  activation  of B  lymphocytes, as  indicated  by  a 
concomitant increase in total IgM secretion. Consistent with this interpretation is the 
apparently lower average affinity of the  anti-IgG from the  normal cells compared 
with that from the RA cells. In the normal donors there is no in vivo process operative 
to promote the proliferation of clones of cells producing higher affinity anti-IgG, as is 
probably the case in the RA patients. The finding, however, that all normal lympho- 
cytes made some anti-IgG after EBV infection, even though at  far lesser quantities 
than in RA, suggests that B-cell tolerance for IgG does not exist in any normal person. 
In patients with RA, the percentage of IgM with anti-IgG activity was high and 
was  similar  in  the  plasma  and  in  the  supernates of EBV  transformed lymphocyte 
cultures. Here, the EBV infection led to increased anti-IgG secretion as a result of cell 
division and  a  concomitant increase in the absolute number of anti-IgG reactive B 
cells.  Similar results would be expected if other diseases associated with high titers of 
anti-IgG activity were studied. In normal subjects, on the other hand, the fraction of 
IgM with anti-IgG activity was low in the plasma and rose in the culture supernates 
after  EBV  infection  although  never approaching  the  amount  seen  in  RA.  Thus, 
normal  individuals  probably have fewer B  cells in the peripheral blood capable of 
IgM anti-IgG production than do RA patients.  Furthermore, the majority of these 
cells  are  not  fully  expressed  in  vivo  but  can  respond  to  a  maturation  event,  or 
derepression, that takes place in the EBV containing cultures. 
Our experiments also show that peripheral blood B lymphocytes from RA patients 
frequently transform in tissue culture in the absence of superinfection with EBV. This 
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inflammatory  diseases  associated  with  B-cell  activation.  Our  current  studies  are 
investigating this possibility.  Nevertheless, with  the exception of certain neoplastic 
states, human B cells usually must already contain EBV genetic material if they are 
to transform and develop into permanent cell lines (4) and this may be of particular 
interest in RA. The mechanisms controlling the frequency with which transformation 
occurs are not fully understood. Contributing factors may include the number of EBV 
genomes per cell, the sensitivity of these genomes to activation, and the presence or 
absence of virus-specific suppressor cells (7,  11,  12). 
One must  always be cautious in interpreting the results of in vitro experiments, 
which  are  necessarily restricted  and  seldom  reflect  precise  conditions  in  a  whole 
organism.  However, polyclonal B-cell stimulation  by clinical EBV infection appar- 
ently occurs in infectious mononucleosis, as evidenced by IgM anti-IgG and heterophil 
antibodies, and elevated total serum IgM concentrations which sometimes persist for 
up  to 2 yr after clinical  infection (13).  Possible outcomes of clinical  infection with 
EBV  that  have  previously been  considered  are:  recovery with  establishment  of a 
latent state, malignant transformation, and immunodeficiency (14). Both genetic and 
environmental factors apparently influence the ultimate result (15).  It does not seem 
unreasonable to consider autoimmune disease as another theoretically possible result. 
Summary 
Peripheral blood mononuclear cells from 10 patients with rheumatoid arthritis and 
9 control subjects were cultured in vitro for 30 days with and without infection by 
Epstein-Barr virus. All cultures showed polyclonal stimulation of B cells as indicated 
by rising levels of IgM in the culture supernates, reaching maximal at  18-24 days, 
and with no quantitative or kinetic difference between the RA and control cells.  IgM 
anti-IgG was  also  produced  in  both  groups  and  maximally at  18-24  days,  but  in 
greater quantity by the RA lymphocytes. The anti-IgG made by the RA lymphocytes 
was  more easily absorbed  by solid  phase IgG than  was  the anti-IgG made by the 
normal lymphoeytes and thus was judged to be of higher affinity. RA lymphocytes 
uninfected with EBV had higher transformation scores than did the normal controls 
and developed spontaneously into permanent cell lines in six instances. 
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